Abstract: Described herein are polynucleotides associated with prostate and lung cancer. The polynucleotides are miRNAs and miRNA precursors. Related methods and compositions that can be used for diagnosis, prognosis, and treatment of those medical conditions are disclosed. Also described herein are methods that can be used to identify modulators of prostate and lung cancer.
Type:
Grant
Filed:
August 13, 2015
Date of Patent:
May 16, 2017
Assignee:
Rosetta Genomics Ltd.
Inventors:
Itzhak Bentwich, Amir Avniel, Yael Karov, Ranit Aharonov
Abstract: Described herein are novel polynucleotides associated with prostate and lung cancer. The polynucleotides are miRNAs and miRNA precursors. Related methods and compositions that can be used for diagnosis, prognosis, and treatment of those medical conditions are disclosed. Also described herein are methods that can be used to identify modulators of prostate and lung cancer.
Type:
Grant
Filed:
July 13, 2016
Date of Patent:
May 16, 2017
Assignee:
Rosetta Genomics Ltd.
Inventors:
Itzhak Bentwich, Amir Avniel, Yael Karov, Ranit Aharonov
Abstract: The present invention is based in part on the discovery of a panel of miRs whose levels are increased or decreased in the circulation of chronic systolic HF patients. Accordingly, an extensive panel of miRs was screened in the sera of stable chronic systolic HF patients and the results were compared to an age, gender and ethnically matched control group.
Type:
Grant
Filed:
May 23, 2012
Date of Patent:
April 25, 2017
Assignees:
Rosetta Genomics Ltd., MOR Research Applications Ltd.
Abstract: Described herein are novel polynucleotides associated with viral infections. The polynucleotides are miRNAs and miRNA precursors. Related methods and compositions that can be used for diagnosis, prognosis, and treatment of those medical conditions are disclosed. Also described herein are methods that can be used to identify modulators of viral infections.
Type:
Grant
Filed:
July 13, 2015
Date of Patent:
April 18, 2017
Assignee:
Rosetta Genomics Ltd.
Inventors:
Itzhak Bentwich, Amir Avniel, Yael Karov, Ranit Aharonov
Abstract: Described herein are compositions and methods for the prediction of the prognosis of ovarian cancer subjects. The present invention further provides methods for distinguishing between histological subtypes of ovarian cancer tumors, and also methods and compositions for the treatment or prevention of ovarian cancer. Specifically the invention relates to microRNA molecules associated with said methods and compositions, as well as various nucleic acid molecules relating thereto or derived therefrom.
Type:
Grant
Filed:
May 19, 2009
Date of Patent:
January 10, 2017
Assignees:
Rosetta Genomics Ltd., MOR Research Applications
Abstract: Provided herein are methods for the treatment of liver cancer. These methods encompass the administration of a compound comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Also provided herein are compositions for the treatment of liver cancer. Such compositions include compounds comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Certain miRNAs have been identified as overexpressed in liver cancer, such as, for example, hepatocellular carcinoma, and are thus selected for targeting by modified oligonucleotides. Further, certain miRNAs have been identified as overexpressed in hepatocellular carcinoma cells exposed to dioxin, and are thus selected for targeting by modified oligonucleotides. Antisense inhibition of certain of these miRNAs has been found to inhibit cell proliferation and induce apoptosis.
Abstract: The disclosure provides compositions and methods for treating an ovarian cancer in a subject. More specifically, the disclosure provides microRNA (miRNA) inhibitor molecules that target to different miRNAs for treating different types of ovarian cancers in a subject. Furthermore, different modifications of miRNA inhibitor molecules as well as different derivatives of miRNA inhibitor molecules are also described.
Abstract: The present invention provides a method for classification of kidney tumors through the analysis of the expression patterns of specific microRNAs and nucleic acid molecules relating thereto. Classification according to a microRNA expression framework allows optimization of treatment, and determination of specific therapy.
Type:
Grant
Filed:
January 30, 2014
Date of Patent:
May 17, 2016
Assignees:
Rosetta Genomics, Ltd., Tel Hashomer Medical Research Infrastructure and Services Ltd.
Inventors:
Nitzan Rosenfeld, Yael Spector, Eddie Friedman, Zohar Dotan
Abstract: The present invention provides methods and compositions for identifying subjects at risk of developing a complication of pregnancy, such as preeclampsia or preterm labor. The compositions are microRNAs and associated nucleic acids.
Type:
Grant
Filed:
October 25, 2013
Date of Patent:
May 10, 2016
Assignees:
Rosetta Genomics Ltd., MOR Research Applications
Abstract: Described herein are compositions and methods for prognosis and treatment of prostate cancer patients. Specifically the invention relates to microRNA molecules associated with the prognosis of prostate cancer, as well as various nucleic acid molecules relating thereto or derived therefrom.
Abstract: Provided herein are methods for the treatment of liver cancer. These methods encompass the administration of a compound comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Also provided herein are compositions for the treatment of liver cancer. Such compositions include compounds comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Certain miRNAs have been identified as overexpressed in liver cancer, such as, for example, hepatocellular carcinoma, and are thus selected for targeting by modified oligonucleotides. Further, certain miRNAs have been identified as overexpressed in hepatocellular carcinoma cells exposed to dioxin, and are thus selected for targeting by modified oligonucleotides. Antisense inhibition of certain of these miRNAs has been found to inhibit cell proliferation and induce apoptosis.
Abstract: The present invention provides nucleic acid sequences that are used for identification and diagnosis of specific cancers. The nucleic acid sequences can also be used for prognosis evaluation of a subject based on the expression profile of a biological sample.
Abstract: Described herein are polynucleotides associated with prostate and lung cancer. The polynucleotides are miRNAs and miRNA precursors. Related methods and compositions that can be used for diagnosis, prognosis, and treatment of those medical conditions are disclosed. Also described herein are methods that can be used to identify modulators of prostate and lung cancer.
Type:
Grant
Filed:
May 8, 2013
Date of Patent:
September 15, 2015
Assignee:
Rosetta Genomics Ltd.
Inventors:
Itzhak Bentwich, Amir Avniel, Yael Karov, Ranit Aharonov
Abstract: The present invention provides a process for classification of cancers and tissues of origin through the analysis of the expression patterns of specific microRNAs and nucleic acid molecules relating thereto. Classification according to a microRNA tree-based expression framework allows optimization of treatment, and determination of specific therapy.
Abstract: The invention relates to methods for detecting an altered susceptibility to breast and ovarian cancer in a subject carrying a BRCA mutation, comprising determining the nucleic acid sequence of a polymorphism of a microRNA-related gene.
Type:
Grant
Filed:
November 30, 2009
Date of Patent:
July 28, 2015
Assignees:
Rosetta Genomics Ltd., Tel Hashomer Medical Research Infrastructure and Services Ltd.
Abstract: The present invention provides a method for classification of kidney tumors through the analysis of the expression patterns of specific microRNAs and nucleic acid molecules relating thereto. Classification according to a microRNA expression framework allows optimization of treatment, and determination of specific therapy.
Type:
Grant
Filed:
March 5, 2012
Date of Patent:
June 30, 2015
Assignees:
Rosetta Genomics Ltd., Tel Hashomer Medical Research Infrastructure and Services Ltd.
Abstract: Described herein are compositions and methods for modulation of p53-dependent cell death and cell proliferation. The compositions are microRNAs and associated nucleic acids.
Type:
Grant
Filed:
May 19, 2014
Date of Patent:
April 14, 2015
Assignees:
Rosetta Genomics Ltd., Yeda Research and Development Company Ltd.
Abstract: The present invention provides nucleic acid sequences that are used for identification, classification and diagnosis of lung cancers. The present invention further provides microRNA molecules, as well as various nucleic acid molecules relating thereto or derived therefrom, associated with specific types of lung cancers.
Type:
Application
Filed:
December 16, 2014
Publication date:
April 9, 2015
Applicants:
ROSETTA GENOMICS LTD., TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD.
Abstract: The disclosure provides compositions and methods for treating an ovarian cancer in a subject. More specifically, the disclosure provides microRNA (miRNA) inhibitor molecules that target to different miRNAs for treating different types of ovarian cancers in a subject. Furthermore, different modifications of miRNA inhibitor molecules as well as different derivatives of miRNA inhibitor molecules are also described.